Group 1 - CrowdStrike reported Q1 earnings of $0.73 per share on sales of $1.10 billion, exceeding consensus estimates of $0.65 earnings per share on the same sales figure [1] - The company's Q1 revenue increased nearly 20%, but the adjusted operating margin fell 500 basis points year-over-year to 18% due to rising costs in professional services and higher R&D spending [3] - Despite the positive Q1 results, CrowdStrike's stock fell about 7% in extended trading, attributed to a weaker-than-expected Q2 outlook [1][2] Group 2 - CrowdStrike anticipates Q2 earnings of $0.82 per share on revenue of around $1.14 billion, which is below street expectations of $0.81 earnings per share and $1.16 billion in revenue [2] - The company raised its full-year earnings guidance to $3.44 to $3.56 in adjusted earnings per share, above the consensus of $3.43, while maintaining its sales outlook of $4.74 billion to $4.81 billion, aligning with the consensus of $4.77 billion [4] - A $1 billion share buyback program was announced, which may indicate confidence in the company's long-term prospects [4] Group 3 - CrowdStrike's stock has surged 40% this year, significantly outperforming the S&P 500 index's 2% rise, but the stock's lofty valuations may have contributed to investor unease following the minor Q2 revenue forecast miss [5] - The critical question remains whether CRWD stock is overvalued at current levels of $460, necessitating a comparison of its valuation with recent operating performance and financial condition [6]

Core Viewpoint - Regeneron Pharmaceuticals' stock has experienced a significant decline due to the failure of its COPD treatment, itepekimab, in a late-stage clinical trial, which was expected to be a blockbuster drug with peak sales projections between $2 billion and $6 billion [1][14]. Stock Performance - Regeneron shares fell 19% on May 30, trading at $490, which is a 60% decrease from its 52-week peak of approximately $1,200 [2]. - The stock has seen a notable drop of 25.8% from a peak of $738.84 on April 8, 2022, to $548.35 on June 14, 2022, compared to a 25.4% decline for the S&P 500 [13]. Financial Metrics - Regeneron has a price-to-sales (P/S) ratio of 4.6, a price-to-free cash flow (P/FCF) ratio of 16.4, and a price-to-earnings (P/E) ratio of 14.4, compared to 3.0, 20.5, and 26.4 for the S&P 500, respectively [8]. - The company's revenues have grown 7.5% from $13 billion to $14 billion in the past 12 months, while the S&P 500 saw a 5.5% growth [8]. - Regeneron's operating income over the last four quarters was $3.8 billion, with an operating margin of 27.2%, significantly higher than the S&P 500's 13.2% [12]. Profitability and Stability - Regeneron has demonstrated very strong profitability, with a net income margin of 31.9% compared to 11.6% for the S&P 500 [12]. - The company's balance sheet is robust, with a debt total of $2.7 billion and a market capitalization of $52 billion, resulting in a low debt-to-equity ratio of 4.2% [12]. Future Growth Potential - Despite the setback with itepekimab, Regeneron is expected to benefit from the strong growth of Dupixent, which saw sales rise 19% to $3.7 billion last quarter, with potential peak annual sales exceeding $20 billion [14]. - The company has a promising pipeline with over a dozen programs in late-stage trials, indicating future growth opportunities [14].

Company Overview - Snap's shares have increased by approximately 4.8% over the past month, underperforming the S&P 500 index [1] - Recent earnings report indicates a need to analyze catalysts affecting Snap's performance [1] Earnings Estimates - Fresh estimates for Snap have trended downward, with the consensus estimate shifting by -34.58% [2] VGM Scores - Snap has a Growth Score of A, but a Momentum Score of F, and a Value Score of F, placing it in the lowest quintile for value investment strategy [3] - The overall aggregate VGM Score for Snap is C, which is relevant for investors not focused on a single strategy [3] Outlook - The downward trend in estimates suggests a negative outlook for Snap, with a Zacks Rank of 3 (Hold), indicating an expectation of in-line returns in the coming months [4] Industry Comparison - Snap is part of the Zacks Internet - Software industry, where F5 Networks has seen a 7% increase in the past month [5] - F5 reported revenues of $731.12 million for the last quarter, reflecting a year-over-year growth of +7.3% and an EPS of $3.42 compared to $2.91 a year ago [5] - F5 is projected to post earnings of $3.49 per share for the current quarter, with a year-over-year change of +3.9% and a Zacks Consensus Estimate change of -0.8% over the last 30 days [6] - F5 holds a Zacks Rank of 2 (Buy) based on the direction and magnitude of estimate revisions, along with a VGM Score of C [6]

Core Insights - Salesforce reported Q1 fiscal 2026 results with sales of $9.83 billion and earnings per share of $2.58, surpassing consensus estimates of $9.75 billion and $2.53 respectively [1] - The company announced the acquisition of Informatica for $8 billion, marking its largest acquisition since Slack in 2021 [1] - Salesforce raised its full-year forecast for adjusted earnings per share to $11.27-$11.33 and revenue to $41.0 billion-$41.3 billion, exceeding market expectations [1] Financial Performance - Salesforce's revenues grew by 8% to $9.8 billion in the latest quarter compared to $9.1 billion a year earlier, while the S&P 500 saw a 4.8% improvement [9] - The company has achieved an average revenue growth rate of 12.7% over the last three years, compared to 5.5% for the S&P 500 [9] - Salesforce's operating income over the previous four quarters was $7.9 billion, with an operating margin of 20.4%, higher than the S&P 500's 13.2% [12] Valuation Metrics - Salesforce has a price-to-sales (P/S) ratio of 7.1, compared to 3.0 for the S&P 500, and a price-to-earnings (P/E) ratio of 27 against the benchmark's 26.4 [9] - The price-to-free cash flow (P/FCF) ratio stands at 20.6, slightly above the S&P 500's 20.5 [9] - At a stock price of $280, Salesforce is trading at 7 times its trailing revenues [12] Financial Stability - Salesforce's balance sheet is considered robust, with a debt of $11 billion and a market capitalization of $265 billion, resulting in a low debt-to-equity ratio of 4.3% compared to 19.9% for the S&P 500 [12] - Cash and cash equivalents amount to $11 billion, constituting 11% of total assets of $99 billion, which is moderate compared to the S&P 500's 13.8% [12] Downturn Resilience - Salesforce stock has shown more severe impacts during downturns compared to the S&P 500, with a decline of 58.6% from its peak in November 2021 to December 2022 [13] - The stock fully rebounded to its pre-crisis high by March 2024, indicating some resilience [13] - Overall, Salesforce's performance across key metrics is rated as very strong, with financial stability categorized as extremely strong [13]

Core Viewpoint - Chipotle Mexican Grill has underperformed in 2023, with a 15% decline in stock value compared to a 1% gain in the S&P 500, facing challenges in comparable sales and operating margins [1][12] Financial Performance - Revenue increased by 6% to $2.88 billion in the first quarter, while adjusted EPS rose by 7% to $0.29 [1] - Comparable-restaurant sales fell by 0.4%, driven by a 2.3% decrease in transactions, despite a 1.9% increase in average check size [1] - Operating margins compressed by 130 basis points to 26.2%, affected by rising food and labor costs and larger portion sizes [1] - Chipotle's revenue has grown at an average rate of 14.4% over the last three years, significantly outperforming the S&P 500's 6.2% growth [4] - The company expects low single-digit comparable sales growth for the full year 2025, with traffic anticipated to improve in the second half [1] Profitability Metrics - Chipotle's operating income over the last four quarters was $2.0 billion, resulting in a moderate operating margin of 17.5% [5] - The operating cash flow (OCF) was $2.1 billion, reflecting an OCF margin of 18.6% [5] - Net income for the preceding four quarters was $1.5 billion, indicating a net income margin of 13.6% [5] Valuation Comparison - Chipotle's price-to-sales (P/S) ratio is 6.1, compared to 2.8 for the S&P 500, indicating a higher valuation [6] - The price-to-earnings (P/E) ratio stands at 44.7 versus the benchmark's 24.5, suggesting that the stock is expensive [6] Financial Stability - Chipotle's debt was $4.5 billion, with a market capitalization of $70 billion, resulting in a low debt-to-equity ratio of 6.6% [8] - Cash and cash equivalents amount to $1.4 billion, leading to a cash-to-assets ratio of 15.5% [8] Resilience During Downturns - CMG stock has shown slightly better performance than the S&P 500 during recent downturns, indicating some resilience [9] - Historical data shows significant stock declines during past crises, but recovery has been achieved in each case [10][11] Overall Assessment - Chipotle's performance metrics indicate strong growth and financial stability, but high valuation levels suggest limited upside potential in the near term [12][13]

欧洲央行副行长金多斯：股票估值偏高，信贷利差与风险脱节。 ...

智通财经APP获悉，一些华尔街策略师认为，随着欧洲经济前景改善，欧洲股市相对于美国股市的表现 将至少创下20年来最佳水平。根据对20位策略师的调查平均值，欧洲斯托克600指数预计将在年底收于 554点左右。这意味着较上周五收盘上涨约1%。 摩根大通在调查中的目标位最高，为580点，而花旗集团预测该指数将上涨4%至570点，因为分析师们 对企业盈利的悲观情绪有所减弱。相比之下，两家银行都预计美国股市基准指数在今年剩余时间内将下 跌。 摩根大通对欧洲和美国股市的目标位差异表明，斯托克600指数在2025年的表现将比标普500指数高出25 个百分点，创下历史纪录，而花旗的预测则是2005年以来的最佳水平。 花旗策略师贝娅塔·曼泰谈到欧洲股市时表示："如果我们已经度过了盈利不确定性的高峰期，这可能为 进一步上涨和潜在的多重重新评级奠定基础，尤其是在那些受创更严重的周期性行业。" 这一前景标志着与年初预期的转变，当时策略师们预计欧洲股市将大幅落后于美国。但随着德国历史性 的财政改革和富有韧性的盈利吸引了那些寻求替代陷入贸易战的美国资产的投资者，该基准指数已经上 涨。 美国银行一周前公布的一项调查发现，目前全球基金经理中 ...

智通财经APP获悉，国际知名投行巴克莱（Barclays）近期表示，在经历了创纪录的估值下调和迅速的重估之后，美国大型科技股 的交易价格仍比2024年底时低4倍左右 ；它们在2025年第一季度令人瞩目的收益证实了关键增长驱动力依然稳固。标普500指数中 除科技股以外的成分股估值在抛售期间表现更为坚挺，并且尽管消费者板块盈利疲软，其估值已实现超跌反弹。 图 1. 标普 500 指数非科技股估值已完全恢复；大型科技股尽管在 2025 年第一季度出色业绩后重估，但估值仍较年初低 4 倍远期 市盈率（Fwd PE） 尽管关税带来的不确定性可能已过峰值，但消费者和企业在关税实施前的提前采购行为，掩盖了部分尚未在宏观经济硬数据中体 现的经济损害。2025 年第一季度收益好于预期，但在非必需消费品（不含亚马逊）和必需消费品板块中，消费者疲软的迹象明 显，这些板块是少数几个出现每股收益同比收缩以及运营杠杆为负的板块。 鉴于宏观经济硬数据依然稳健、财政赤字担忧加剧且美联储不急于降息，10 年期美国国债收益率上升给股票估值带来挑战。 美国股市（标普 500 指数）因近期贸易紧张局势缓和迹象，几乎抹去了年初至今的所有跌幅。标普50 ...

Core Insights - The article does not provide specific insights or analysis regarding any companies or industries, focusing instead on disclaimers and disclosures related to the author's position and affiliations [1][2]. Group 1 - No stock, option, or similar derivative positions are held by the author in any mentioned companies, nor are there plans to initiate such positions in the near future [1]. - The article expresses the author's personal opinions and is not influenced by compensation from any company [1]. - The views presented may not reflect those of Seeking Alpha as a whole, indicating a potential variance in perspectives among different analysts [2].

证券研究报告 最新A股、港股、美股估值怎么看？ ——估值周报（0428-0430） 全球主要指数估值总览 0 20 40 60 80 100 120 140 160 上证指数 创业板指 恒生指数 恒生科技 标普500 纳斯达克指数 道琼斯工业指数 日经225 德国DAX 中位数 最大值 最小值 现值 A股 港股 美股 日股 德股 图表1：全球主要指数PE(TTM) 注：自2010年1月起，截至2025年5月4日 资料来源： wind ，华西证券研究所 李立峰 SAC NO:S1120520090003 冯逸华 SAC NO:S1120523070007 2025年5月4日 请仔细阅读在本报告尾部的重要法律声明 1.1 A股绝对估值变化 4 图表2、3：A股整体PE(TTM)、A股剔除金融和石油石化PE(TTM，剔除负值) 资料来源： wind ，华西证券研究所 4 14.62 5 10 15 20 25 30 35 2010-01 2011-01 2012-01 2013-01 2014-01 2015-01 2016-01 2017-01 2018-01 2019-01 2020-01 2021-01 20 ...